

Ref No. NLL/CS/2018- 189

Date: 14.11.2018

- 1. National Stock Exchange of India Limited**
Exchange Plaza, C-1, Block - G, Bandra Kurla
Complex,
Bandra (East), MUMBAI - 400 051.
- 2. BSE Limited**
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Financial Results.

Ref: Compliance under Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sirs,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial results for the quarter & half year ended on September 30, 2018 which are enclosed herewith along with the Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Nectar Lifesciences Limited


(Ankita Jain)
Company Secretary

Encl: a.a.

To Whomsoever It May Concern

We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter and half year ended **September 30,2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI(Listing obligation and Disclosure Requirements) Regulation 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim financial information performed by Independent Auditors of the Entity* issued by the Institute of Chartered Accountant of India.This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Ashwani K. Gupta & Associates
Chartered Accountants
Firm Regn. No. 003803N


(ASHWANI KUMAR GUPTA)
PARTNER

Membership No.: 082808

Place: Chandigarh
Date:14.11.2018

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, CIN: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: cs@neclife.com, Website : www.neclife.com

Statement of Standalone Unaudited Financial Results for the Quarter and Half Year ended 30.09.2018

(Rs in Lacs)

S. No	PARTICULARS	Quarter ended			Half Year ended		Year ended
		30-09-2018	30-06-2018	30-09-2017	30-09-2018	30-09-2017	31-03-2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Sales	81,955.49	59,493.82	48,013.29	141,449.31	82,159.40	209,231.93
	Less: GST Recovered	9,706.48	6,222.80	4,683.67	15,929.28	4,683.67	19,240.64
	Revenue From Operations	72,249.01	53,271.02	43,329.62	125,520.03	77,475.73	189,991.29
	Other operating Income	0.62	2.52	-	3.14	4.30	45.14
II	Other Income	144.96	130.97	131.43	275.93	264.42	558.44
III	Total Income (I + II)	72,394.59	53,404.51	43,461.05	125,799.10	77,744.45	190,594.87
IV	Expenses						
	(a) Cost of Materials consumed	56,954.71	40,909.36	28,756.85	97,864.07	49,605.18	138,163.89
	(b) Purchase of Stock in Trade	1,198.67	322.18	364.93	1,520.85	696.22	1,527.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	390.63	(749.52)	979.37	(358.89)	667.35	(3,043.22)
	(d) Excise Duty	-	-	-	-	2,369.13	2,438.15
	(e) Employee benefits expense	2,157.27	2,005.80	1,994.25	4,163.07	3,929.14	7,840.48
	(f) Finance costs	4,355.37	2,992.34	2,758.35	7,347.71	5,433.90	11,520.24
	(g) Depreciation and amortisation expense	1,554.52	1,629.31	1,649.76	3,183.83	3,195.59	6,430.88
	(h) Other expenses	5,161.62	4,777.91	4,771.28	9,939.53	8,494.96	19,460.56
	Total Expenses (IV)	71,772.79	51,887.38	41,274.79	123,660.17	74,391.47	184,338.29
V	Profit/(loss) before exceptional items and tax (III- IV)	621.80	1,517.13	2,186.26	2,138.93	3,352.98	6,256.58
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	621.80	1,517.13	2,186.26	2,138.93	3,352.98	6,256.58
VIII	Tax Expense (1) Current Tax	26.51	144.58	360.06	171.09	360.06	632.18
	(2) Deferred Tax	55.86	52.10	(60.93)	107.96	66.75	408.92
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	539.43	1,320.45	1,887.13	1,859.88	2,926.17	5,215.48
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	109.66
	Total Other Comprehensive Income, (Net of Tax)	-	-	-	-	-	109.66
	Total Comprehensive Income for the period	539.43	1,320.45	1,887.13	1,859.88	2,926.17	5,325.14
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic	0.24	0.59	0.84	0.83	1.30	2.33
	b) Diluted	0.24	0.59	0.84	0.83	1.30	2.33

Notes:

- 1 The above financial results were reviewed by Audit Committee on November 14, 2018 and approved by the Board in its meeting held on November 14, 2018. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone unaudited financial results for the quarter and half year ended on September 30, 2018.
- 2 The Shareholders in their Annual General Meeting held on September 28, 2018 have declared the final dividend of Re. 0.05/- per equity share (5% on the face value of Re. 1/- per equity share) for the financial year 2017-18. The Company has despatched Dividend Demand Drafts to the shareholders at their registered addresses, and wherever applicable, the Dividend has been credited to the shareholders' accounts directly through National Electronic Credit Settlement (NECS/ECS/NEFT/ Direct Credit) facility of RBI.
- 3 The increase in financial expenses is due to abnormal foreign exchange fluctuation loss of Rs. 14.67 Crores during the quarter ended September 30, 2018 (against Gain of Rs. 1.48 Crores during quarter ended September 30, 2017).
- 4 The company is exclusively in the pharmaceutical business segment.
- 5 The Statement of Assets and Liability is attached as Annexure.
- 6 The above financial results are on stand alone basis.

Dated: 14.11.2018

Place: Chandigarh

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

(Dinesh Dua)

Chief Executive Officer & Director

Ashwani K. Gupta

(Ashwani K. Gupta)
M.No 82808

Statement of Standalone Assets and Liabilities

Particulars	As At	
	30-Sep-18 Unaudited	31-Mar-18 Audited
ASSETS		
Non-current assets		
(a) Property, plant and equipment	80,395.27	80,643.13
(b) Capital work-in-progress	10,020.56	9,978.55
(c) Intangible assets	4,062.26	4,592.40
(d) Financial assets		
(i) Investments	60.03	60.03
(ii) Trade receivables	372.83	368.13
(iii) Other financial assets	612.40	611.29
(e) Other non-current assets	10,350.44	10,100.80
Current assets		
(a) Inventory	94,306.40	85,943.48
(b) Financial assets		
(i) Investments	50.95	50.95
(ii) Trade receivables	52,722.45	61,211.55
(iii) Cash and cash equivalents	3,397.16	890.83
(iv) Loans	32.04	37.88
(v) Other financial assets	9,849.83	11,223.15
(c) Other current assets	10,335.20	6,677.20
Total Assets	276,567.82	272,389.37
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	2,242.61	2,242.61
(b) Other equity	105,480.17	103,620.29
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	19,262.95	22,007.62
(ii) Other financial liabilities	1,657.82	1,756.45
(iii) Other Non-Current Liability	88.33	89.58
(b) Provisions	906.88	906.88
(c) Deferred tax liabilities (net)	10,941.80	10,833.85
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	68,155.58	63,408.26
(ii) Trade payables	49,337.52	53,942.38
(iii) Other financial liabilities	13,594.90	11,233.70
(b) Other current liabilities	3,247.22	1,106.64
(c) Provisions	65.55	48.81
(d) Current tax liabilities (net)	1,586.49	1,192.30
Total equity and liabilities	276,567.82	272,389.37

